Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Wr-McCr LLC

Neither a doctor nor a teaching hospital

Research payments

$2,092,518

279 payments

Through program year 2025, Wr-McCr LLC is reported as receiving $2,092,518 in research payments, across 279 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $47,718 12
2024 Research $25,545 18
2023 Research $150,093 50
2022 Research $359,495 43
2021 Research $202,519 42
2020 Research $423,222 62
2019 Research $883,926 52

Breakdown

Who paid Research payments · program years 2019–2025
  1. Allergan Inc. $687,857 84 payments
  2. Janssen Research & Development, LLC $425,384 53 payments
  3. Eli Lilly and Company $366,702 18 payments
  4. AbbVie, Inc. $169,151 39 payments
  5. GlaxoSmithKline, LLC. $127,202 34 payments
  6. Bausch Health US, LLC $121,288 12 payments
  7. AMAG Pharmaceuticals, Inc. $97,075 5 payments
  8. Novo Nordisk AS $39,781 7 payments
  9. Ferring International Pharmascience Center US $34,244 7 payments
  10. Sumitomo Pharma America, Inc. $9,598 12 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Study Evaluating the Efficacy and Safety of BOTOX Intravesical Instillation in Patients with Overactive Bladder and Urinary Incontinence $326,648 28 payments
  2. A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older $293,135 23 payments
  3. A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-To-Severe Plaque Psoriasis $191,101 2 payments
  4. A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Longterm Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $159,910 13 payments
  5. A Randomized double blind Placebo Controlled Phase 3 Study to Evaluate 3 Dose Levels of Ad26.COV2.S Administered As Single Dose And Two Dose Schedules in Healthy Adults $132,249 30 payments
  6. Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Efficacysafety Study $121,288 12 payments
  7. Prasterone DHEA for the Treatment of Hypoactive Sexual Desire Disorder HSDD - Placebo-Controlled, Double Blind and Randomized Phase III Study of Intravaginal Prasterone $97,075 5 payments
  8. M16-837 $90,317 12 payments
  9. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis $85,065 1 payment
  10. A Phase 3, Observer-Blind, Randomized, Placebo Controlled Study to Eva $81,684 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record